دورية أكاديمية
A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers
| العنوان: | A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers |
|---|---|
| المؤلفون: | Kristin L. Ayers, Meng Ma, Gaspard Debussche, David Corrigan, Jonathan McCafferty, Kyeryoung Lee, Scott Newman, Xiang Zhou, Fred R. Hirsch, Philip C. Mack, Jane J. Liu, Eric E. Schadt, Rong Chen, Shuyu D. Li |
| المصدر: | BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021) |
| بيانات النشر: | BMC, 2021. |
| سنة النشر: | 2021 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | Non-small cell lung cancer, Immune checkpoint inhibitor, Neutrophil-lymphocyte ratio, Anemia, Biomarker, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Abstract Background Immune checkpoint inhibitors (ICIs) have been incorporated into various clinical oncology guidelines for systemic treatment of advanced non-small cell lung cancers (aNSCLC). However, less than 50% (and 20%) of the patients responded to the therapy as a first (or second) line of therapy. PD-L1 immunohistochemistry (IHC) is an extensively studied biomarker of response to ICI, but results from this test have equivocal predictive power. In order to identify other biomarkers that support clinical decision-making around whether to treat with ICIs or not, we performed a retrospective study of patients with aNSCLC who underwent ICI-based therapy in the Mount Sinai Health System between 2014 and 2019. Methods We analyzed data from standard laboratory tests performed in patients as a part of the routine clinical workup during treatment, including complete blood counts (CBC) and a comprehensive metabolic panel (CMP), to correlate test results with clinical response and survival. Results Of 11,138 NSCLC patients identified, 249 had been treated with ICIs. We found associations between high neutrophil-to-lymphocyte ratio (NLR ≥ 5) and poor survival in ICI-treated NSCLC. We further observed that sustained high NLR after initiation of treatment had a more profound impact on survival than baseline NLR, regardless of PD-L1 status. Hazard ratios when comparing patients with NLR ≥ 5 vs. NLR |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1471-2407 75591154 |
| Relation: | https://doaj.org/toc/1471-2407 |
| DOI: | 10.1186/s12885-021-08194-9 |
| URL الوصول: | https://doaj.org/article/058ce0ca61b446488b516bf75591154b |
| رقم الأكسشن: | edsdoj.058ce0ca61b446488b516bf75591154b |
| قاعدة البيانات: | Directory of Open Access Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 14712407 75591154 |
|---|---|
| DOI: | 10.1186/s12885-021-08194-9 |